352 related articles for article (PubMed ID: 28237034)
1. Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I.
Ekins S; Godbole AA; Kéri G; Orfi L; Pato J; Bhat RS; Verma R; Bradley EK; Nagaraja V
Tuberculosis (Edinb); 2017 Mar; 103():52-60. PubMed ID: 28237034
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison.
Godbole AA; Ahmed W; Bhat RS; Bradley EK; Ekins S; Nagaraja V
Biochem Biophys Res Commun; 2014 Apr; 446(4):916-20. PubMed ID: 24642256
[TBL] [Abstract][Full Text] [Related]
3. Targeting Mycobacterium tuberculosis topoisomerase I by small-molecule inhibitors.
Godbole AA; Ahmed W; Bhat RS; Bradley EK; Ekins S; Nagaraja V
Antimicrob Agents Chemother; 2015 Mar; 59(3):1549-57. PubMed ID: 25534741
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays.
Sandhaus S; Chapagain PP; Tse-Dinh YC
Sci Rep; 2018 Jan; 8(1):1437. PubMed ID: 29362471
[TBL] [Abstract][Full Text] [Related]
5. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
[TBL] [Abstract][Full Text] [Related]
6. Characterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters.
Temesszentandrási-Ambrus C; Tóth S; Verma R; Bánhegyi P; Szabadkai I; Baska F; Szántai-Kis C; Hartkoorn RC; Lingerfelt MA; Sarkadi B; Szakács G; Őrfi L; Nagaraja V; Ekins S; Telbisz Á
PLoS One; 2018; 13(9):e0202749. PubMed ID: 30183750
[TBL] [Abstract][Full Text] [Related]
7. Small-Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents.
Sandhaus S; Annamalai T; Welmaker G; Houghten RA; Paz C; Garcia PK; Andres A; Narula G; Rodrigues Felix C; Geden S; Netherton M; Gupta R; Rohde KH; Giulianotti MA; Tse-Dinh YC
Antimicrob Agents Chemother; 2016 Jul; 60(7):4028-36. PubMed ID: 27114277
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential Mycobacterium tuberculosis topoisomerase I inhibitors: a study against active, dormant and resistant tuberculosis.
Sridevi JP; Suryadevara P; Janupally R; Sridhar J; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Eur J Pharm Sci; 2015 May; 72():81-92. PubMed ID: 25769524
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
[TBL] [Abstract][Full Text] [Related]
10. Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target.
Ravishankar S; Ambady A; Awasthy D; Mudugal NV; Menasinakai S; Jatheendranath S; Guptha S; Sharma S; Balakrishnan G; Nandishaiah R; Ramachandran V; Eyermann CJ; Reck F; Rudrapatna S; Sambandamurthy VK; Sharma UK
Tuberculosis (Edinb); 2015 Sep; 95(5):589-98. PubMed ID: 26073894
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
12. Shortening the treatment of tuberculosis.
Mitchison DA
Nat Biotechnol; 2005 Feb; 23(2):187-8. PubMed ID: 15696148
[No Abstract] [Full Text] [Related]
13. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
Singh S; Roy KK; Khan SR; Kashyap VK; Sharma A; Jaiswal S; Sharma SK; Krishnan MY; Chaturvedi V; Lal J; Sinha S; Dasgupta A; Srivastava R; Saxena AK
Bioorg Med Chem; 2015 Feb; 23(4):742-52. PubMed ID: 25614114
[TBL] [Abstract][Full Text] [Related]
14. Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.
Blanco D; Perez-Herran E; Cacho M; Ballell L; Castro J; González Del Río R; Lavandera JL; Remuiñán MJ; Richards C; Rullas J; Vázquez-Muñiz MJ; Woldu E; Zapatero-González MC; Angulo-Barturen I; Mendoza A; Barros D
Antimicrob Agents Chemother; 2015 Apr; 59(4):1868-75. PubMed ID: 25583730
[TBL] [Abstract][Full Text] [Related]
15. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
Saxena S; Samala G; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 Apr; 23(7):1402-12. PubMed ID: 25766629
[TBL] [Abstract][Full Text] [Related]
16. Characterization of DNA topoisomerase I from Mycobacterium tuberculosis: DNA cleavage and religation properties and inhibition of its activity.
Godbole AA; Leelaram MN; Bhat AG; Jain P; Nagaraja V
Arch Biochem Biophys; 2012 Dec; 528(2):197-203. PubMed ID: 23085346
[TBL] [Abstract][Full Text] [Related]
17. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase I and DNA gyrase as targets for TB therapy.
Nagaraja V; Godbole AA; Henderson SR; Maxwell A
Drug Discov Today; 2017 Mar; 22(3):510-518. PubMed ID: 27856347
[TBL] [Abstract][Full Text] [Related]
19. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
Andries K; Verhasselt P; Guillemont J; Göhlmann HW; Neefs JM; Winkler H; Van Gestel J; Timmerman P; Zhu M; Lee E; Williams P; de Chaffoy D; Huitric E; Hoffner S; Cambau E; Truffot-Pernot C; Lounis N; Jarlier V
Science; 2005 Jan; 307(5707):223-7. PubMed ID: 15591164
[TBL] [Abstract][Full Text] [Related]
20. When inhibitors do not inhibit: critical evaluation of rational drug design targeting chorismate mutase from Mycobacterium tuberculosis.
Munack S; Leroux V; Roderer K; Ökvist M; van Eerde A; Gundersen LL; Krengel U; Kast P
Chem Biodivers; 2012 Nov; 9(11):2507-27. PubMed ID: 23161632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
